Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 35.40 NOK
Change Today -1.40 / -3.80%
Volume 53.2K
NANO On Other Exchanges
As of 10:25 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

nordic nanovector asa (NANO) Snapshot

36.80 NOK
Previous Close
36.80 NOK
Day High
37.00 NOK
Day Low
35.30 NOK
52 Week High
01/28/15 - 39.00 NOK
52 Week Low
12/18/14 - 27.90 NOK
Market Cap
Average Volume 10 Days
-3.81 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NORDIC NANOVECTOR ASA (NANO)

Related News

No related news articles were found.

nordic nanovector asa (NANO) Related Businessweek News

No Related Businessweek News Found

nordic nanovector asa (NANO) Details

Nordic Nanovector ASA, a biotech company, develops, manufactures, and delivers antibody-radionuclide-conjugate (ARC) clinical solutions to address unmet medical needs and advance cancer care in patients. Its lead product candidate is Betalutin, an ARC that is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.

19 Employees
Last Reported Date: 02/23/15
Founded in 2009

nordic nanovector asa (NANO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 907.3K NOK
Chief Financial Officer
Total Annual Compensation: 1.1M NOK
Chief Operations Officer
Total Annual Compensation: 1.3M NOK
Chief Quality Officer
Total Annual Compensation: 868.1K NOK
Chief Clinical Officer
Total Annual Compensation: 741.2K NOK
Compensation as of Fiscal Year 2014.

nordic nanovector asa (NANO) Key Developments

Nordic Nanovector Appoints New Scientific Advisory Board

Nordic Nanovector ASA announced the formation of a new Scientific Advisory Board (SAB). The SAB includes experts in haematology-oncology and cancer drug development from academic/research institutions in the US and Europe. The SAB will be chaired by: Prof. Timothy Illidge (UK): Professor of Targeted Therapy and Oncology and Honorary Consultant in Oncology, University of Manchester and Christie NHS Trust; Prof. Pierluigi Zinzani (Italy): Associate Professor of Hematology at the Institute of Hematology 'L. e A. Seràgnoli,' University of Bologna. In addition, the SAB includes: Dr. Arne Kolstad (Norway): Senior Consultant in Medical Oncology and Radiotherapy at Oslo University Hospital Radiumhospitalet.; Prof. Dolores Caballero (Spain): Head of Clinic and Transplant Unit at the University Hospital, Salamanca; Prof. Stephen Schuster (USA): Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma, Associate Professor of Medicine, and Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine; Prof. Armando Lopez-Guillermo (Spain): Senior Consultant at the Department of Hematology in Hospital Clinic, Barcelona; Prof. Francesco D’Amore (Denmark): Clinical Professor in Malignant Lymphoproliferative Diseases at the Department of Hematology, Aarhus University Hospital; Prof. Mark Kaminski (USA): Professor of Hematology/Oncology, University of Michigan; Prof. Wojciech Jurczak (Poland): Professor of Hematology at Jagiellonian University, Cracow; Prof. Lorenz Trumper (Germany): Head of the Department of Hematology and Medical Oncology, University Medical Center Göttingen; Prof. Morschhauser (France). Professor of Hematology and Head of the Lymphoma Unit in the Department of Hematology at the Centre Hospitalier Universitaire de Lille, in Lille.

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA as resolved by the annual general meeting, the company's board of directors will with effect from March 12, 2015 consist of the Per Samuelsson, Hilde H. Steineger and Gisela M. Schwab. Alexandra Morris is by law prevented from being a board member in a listed company due to her position as a portfolio manager at Odin Fund Management and she was thus not available for re-election. Alexandra Morris is being replaced by Gisela M. Schwab. Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008 of Exelixis Inc. From August 2011 to July 2014 Dr. Schwab has served as a member of the board of directors of Topotarget A/S.

Nordic Nanovector ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Nordic Nanovector ASA reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. Revenues for the fourth quarter ended December 2014 amounted to NOK 0.13 million compared to NOK 0.07 million fourth quarter ended December 2013. Operating loss was NOK 29,198,423 compared to NOK 9,179,066 a year ago. Loss before income tax was NOK 26,776,345 compared to NOK 8,526,098 a year ago. Loss for the period attributable to owners of the parent was NOK 26,820,314 or NOK 1.03 per basic and diluted share compared to NOK 8,526,098 or NOK 0.77 per basic and diluted share a year ago. Revenues for the twelve months ended December 2014 and December 2013 amounted to NOK 0.4 million compared to NOK 0.3 million respectively. Operating loss was NOK 68,669,600 compared to NOK 18,111,110 a year ago. Loss before income tax was NOK 63,628,911 compared to NOK 17,010,937 a year ago. Loss for the period attributable to owners of the parent was NOK 63,672,880 or NOK 3.54 per basic and diluted share compared to NOK 17,010,937 or NOK 1.92 per basic and diluted share a year ago. Total cash outflow operating activities for the Group was net NOK 58.2 million in 2014, compared to NOK 14.2 million in 2013. Investment in property plant and equipment was NOK 1,582,442 compared to NOK 296,277 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:NO 35.40 NOK -1.40

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,112.7x
Price/Book 2.9x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORDIC NANOVECTOR ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at